161 related articles for article (PubMed ID: 31647614)
1. Impaired glucose tolerance and albuminuria in patients with chronic heart failure: a subanalysis of the SUPPORT trial.
Nochioka K; Sakata Y; Miura M; Shiroto T; Takahashi J; Saga C; Ikeno Y; Shiba N; Shinozaki T; Sugi M; Nakagawa M; Komaru T; Kato A; Nozaki E; Iwabuchi K; Hiramoto T; Inoue K; Ohe M; Tamaki K; Tsuji I; Shimokawa H
ESC Heart Fail; 2019 Dec; 6(6):1252-1261. PubMed ID: 31647614
[TBL] [Abstract][Full Text] [Related]
2. Clinical impacts of additive use of olmesartan in hypertensive patients with chronic heart failure: the supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial.
Sakata Y; Shiba N; Takahashi J; Miyata S; Nochioka K; Miura M; Takada T; Saga C; Shinozaki T; Sugi M; Nakagawa M; Sekiguchi N; Komaru T; Kato A; Fukuchi M; Nozaki E; Hiramoto T; Inoue K; Goto T; Ohe M; Tamaki K; Ibayashi S; Ishide N; Maruyama Y; Tsuji I; Shimokawa H; ;
Eur Heart J; 2015 Apr; 36(15):915-23. PubMed ID: 25637937
[TBL] [Abstract][Full Text] [Related]
3. Predicting heart failure events in patients with coronary heart disease and impaired glucose tolerance: Insights from the Acarbose Cardiovascular Evaluation (ACE) trial.
Wamil M; McMurray JJV; Scott CAB; Coleman RL; Sun Y; Standl E; Rydén L; Holman RR
Diabetes Res Clin Pract; 2020 Dec; 170():108488. PubMed ID: 33035598
[TBL] [Abstract][Full Text] [Related]
4. Impaired Glucose Tolerance or Newly Diagnosed Diabetes Mellitus Diagnosed during Admission Adversely Affects Prognosis after Myocardial Infarction: An Observational Study.
George A; Bhatia RT; Buchanan GL; Whiteside A; Moisey RS; Beer SF; Chattopadhyay S; Sathyapalan T; John J
PLoS One; 2015; 10(11):e0142045. PubMed ID: 26571120
[TBL] [Abstract][Full Text] [Related]
5. Effect of valsartan on kidney outcomes in people with impaired glucose tolerance.
Currie G; Bethel MA; Holzhauer B; Haffner SM; Holman RR; McMurray JJV
Diabetes Obes Metab; 2017 Jun; 19(6):791-799. PubMed ID: 28093841
[TBL] [Abstract][Full Text] [Related]
6. Association of Empagliflozin Treatment With Albuminuria Levels in Patients With Heart Failure: A Secondary Analysis of EMPEROR-Pooled.
Ferreira JP; Zannad F; Butler J; Filippatos G; Pocock SJ; Brueckmann M; Steubl D; Schueler E; Anker SD; Packer M
JAMA Cardiol; 2022 Nov; 7(11):1148-1159. PubMed ID: 36129693
[TBL] [Abstract][Full Text] [Related]
7. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study.
Anand SS; Dagenais GR; Mohan V; Diaz R; Probstfield J; Freeman R; Shaw J; Lanas F; Avezum A; Budaj A; Jung H; Desai D; Bosch J; Yusuf S; Gerstein HC;
Eur J Prev Cardiol; 2012 Aug; 19(4):755-64. PubMed ID: 21551215
[TBL] [Abstract][Full Text] [Related]
8. Abnormal glucose metabolism in acute myocardial infarction: influence on left ventricular function and prognosis.
Høfsten DE; Løgstrup BB; Møller JE; Pellikka PA; Egstrup K
JACC Cardiovasc Imaging; 2009 May; 2(5):592-9. PubMed ID: 19442946
[TBL] [Abstract][Full Text] [Related]
9. Nonalbuminuric Diabetic Kidney Disease and Risk of All-Cause Mortality and Cardiovascular and Kidney Outcomes in Type 2 Diabetes: Findings From the Hong Kong Diabetes Biobank.
Jin Q; Luk AO; Lau ESH; Tam CHT; Ozaki R; Lim CKP; Wu H; Jiang G; Chow EYK; Ng JK; Kong APS; Fan B; Lee KF; Siu SC; Hui G; Tsang CC; Lau KP; Leung JY; Tsang MW; Kam G; Lau IT; Li JK; Yeung VT; Lau E; Lo S; Fung S; Cheng YL; Chow CC; Huang Y; Lan HY; Szeto CC; So WY; Chan JCN; Ma RCW;
Am J Kidney Dis; 2022 Aug; 80(2):196-206.e1. PubMed ID: 34999159
[TBL] [Abstract][Full Text] [Related]
10. Reduced plasma levels of glucagon-like peptide-1 in elderly men are associated with impaired glucose tolerance but not with coronary heart disease.
Nathanson D; Zethelius B; Berne C; Holst JJ; Sjöholm A; Nyström T
Diabetologia; 2010 Feb; 53(2):277-80. PubMed ID: 19936703
[TBL] [Abstract][Full Text] [Related]
11. Abnormal glucose tolerance contributes to the progression of chronic heart failure in patients with dilated cardiomyopathy.
Kim J; Nakatani S; Hashimura K; Komamura K; Kanzaki H; Asakura M; Asanuma H; Kokubo Y; Tomoike H; Kitakaze M
Hypertens Res; 2006 Oct; 29(10):775-82. PubMed ID: 17283864
[TBL] [Abstract][Full Text] [Related]
12. Impaired glucose tolerance and future cardiovascular risk after coronary revascularization: a 10-year follow-up report.
Tsuchida K; Mitsuma W; Sato Y; Ozaki K; Soda S; Hatada K; Tanaka K; Hosaka Y; Imai S; Takahashi K; Matsubara T; Oda H
Acta Diabetol; 2020 Feb; 57(2):173-182. PubMed ID: 31375898
[TBL] [Abstract][Full Text] [Related]
13. Gender differences in screening for glucose perturbations, cardiovascular risk factor management and prognosis in patients with dysglycaemia and coronary artery disease: results from the ESC-EORP EUROASPIRE surveys.
Ferrannini G; De Bacquer D; Vynckier P; De Backer G; Gyberg V; Kotseva K; Mellbin L; Norhammar A; Tuomilehto J; Wood D; Rydén L;
Cardiovasc Diabetol; 2021 Feb; 20(1):38. PubMed ID: 33573665
[TBL] [Abstract][Full Text] [Related]
14. Nature and prognostic importance of abnormal glucose tolerance and diabetes in acute heart failure.
Berry C; Brett M; Stevenson K; McMurray JJ; Norrie J
Heart; 2008 Mar; 94(3):296-304. PubMed ID: 17664189
[TBL] [Abstract][Full Text] [Related]
15. Modifiability of Composite Cardiovascular Risk Associated With Chronic Kidney Disease in Type 2 Diabetes With Finerenone.
Agarwal R; Pitt B; Rossing P; Anker SD; Filippatos G; Ruilope LM; Kovesdy CP; Tuttle K; Vaduganathan M; Wanner C; Bansilal S; Gebel M; Joseph A; Lawatscheck R; Bakris GL
JAMA Cardiol; 2023 Aug; 8(8):732-741. PubMed ID: 37314801
[TBL] [Abstract][Full Text] [Related]
16. Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study.
Kabootari M; Hasheminia M; Azizi F; Mirbolouk M; Hadaegh F
Cardiovasc Diabetol; 2020 Mar; 19(1):41. PubMed ID: 32228577
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of impaired fasting glycemia, impaired glucose tolerance, and type 2 diabetes in hemodialyzed patients when applying new diagnostic criteria.
Elbert A; Schreier L; Galli C; Beresan H; Lopez G; Traversa M; Berg G
J Ren Nutr; 2006 Oct; 16(4):300-3. PubMed ID: 17046613
[TBL] [Abstract][Full Text] [Related]
18. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
[TBL] [Abstract][Full Text] [Related]
19. Transient impaired glucose tolerance in South African Indians does not carry a risk for progression to NIDDM.
Motala AA; Omar MA; Gouws E
Diabetes Care; 1997 Jul; 20(7):1101-7. PubMed ID: 9203444
[TBL] [Abstract][Full Text] [Related]
20. Albuminuria in chronic heart failure: prevalence and prognostic importance.
Jackson CE; Solomon SD; Gerstein HC; Zetterstrand S; Olofsson B; Michelson EL; Granger CB; Swedberg K; Pfeffer MA; Yusuf S; McMurray JJ;
Lancet; 2009 Aug; 374(9689):543-50. PubMed ID: 19683640
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
